Drug Trial Radar · NCT06611696
Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
Last checked: Nov 20, 2026Latest source record: May 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Nov 15, 2024
Primary completion
Mar 31, 2027
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Chiba UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kissei Pharmaceutical Co., Ltd.; International University of Health and Welfare
- First posted
- Sep 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if avacopan in combination with short-term (4 weeks) reduced-dose glucocorticoid and rituximab works to treat patients with newly-onset ANCA-associated vasculitis. It will also learn about the long-term safety of avacopan. The main questions it aims to answer are: Is avacopan in combination with short-term reduced-dose glucocorticoid and rituximab as effective as the combination of 20 week reduced-dose glucocorticoid and rituximab in the proportion of the patients achieving remission? Does avacopan lower the relapse rate compared to the 6 monthly rituximab maintenance therapy? What medical problems do participants have when taking long-term avacopan? Participants will: Be treated with avacopan in combination with short-term (until 4 weeks) reduced-dose glucocorticoid and rituximab (at 0 week) or reduced-dose glucocorticoid (until 20 weeks) and rituximab (at 0, 26, 52 and 78 weeks). Be assessed at 0, 4, 8, 16, 26, 52, 78 and 104 weeks regarding disease status (remission/relapse), disease activity by Birmingham Vasculitis Activity Score ver3, disease damage by Vasculitis Damage Index and adverse events. The primary endpoint is remission rates at 26 weeks.
Conditions
- ANCA Associated Vasculitis (AAV)
Interventions
Avacopan, prednisolone and rituximabDrug
Patients in the avacoapn group will be treated with avacoapn, short-term reduced-dose prednisolone and rituximab.
Prednisolone and rituximabDrug
Patients in the glucocorticoid arm will be treated with reduced-dose prednisolone and rituximab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportions of patients achieving remissionTime frame: 26 weeks
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan · Not yet recruiting
Asahi General Hospital
Asahi, Chiba, Japan · Recruiting
Chiba Aoba Municipal Hospital
Chiba, Chiba, Japan · Recruiting
Chiba University
Chiba, Chiba, Japan · Recruiting
Chiba Rosai Hospital
Ichihara, Chiba, Japan · Recruiting
Kameda Medical Centre
Kamogawa, Chiba, Japan · Recruiting
International University of Health and Welfare
Narita, Chiba, Japan · Recruiting
Japanese Red Cross Narita Hospital
Narita, Chiba, Japan · Recruiting
Gunma University
Maebashi, Gunma, Japan · Recruiting
Kagawa University
Hiragi, Kagawa-ken, Japan · Recruiting
St.Marianna University School of Medicine
Kawasaki, Kanagawa, Japan · Recruiting
Tohoku Univerisity
Sendai, Miyagi, Japan · Recruiting
Nagasaki University
Nagasaki, Nagasaki, Japan · Recruiting
Okayama University
Okayama, Okayama-ken, Japan · Recruiting
Kitano Hospital
Osaka, Osaka, Japan · Recruiting
Saitama Medical University
Kawagoe, Saitama, Japan · Recruiting
Dokkyo Medical University
Mibu, Tochigi, Japan · Recruiting
Juntendo Univeristy
Bunkyoku, Tokyo, Japan · Recruiting
Kyorin University
Mitaka, Tokyo, Japan · Recruiting
Toho University
Ōta-ku, Tokyo, Japan · Recruiting
Teikyo University
tabashi City, Tokyo, Japan · Recruiting
Yamanashi University
Chuo-shi, Yamanashi, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.